Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $56.20M | $-36.64M | $-1.01 |
| 2024 | $59.63M | $-72.21M | $-2.12 |
| 2023 | $50.23M | $-36.40M | $-1.13 |
| 2022 | $46.85M | $-33.56M | $-1.07 |
| 2021 | $42.21M | $-22.17M | $-0.79 |
Social Signal Score
Earnings
Mon, Nov 9(in 3 months)
Consensus estimate $-0.16 per share
Typical surprise +8.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.11 vs $-0.14beat
- Wed, May 6$-0.22 vs $-0.15miss
- Tue, Mar 3$-0.05 vs $-0.06beat
- Mon, Nov 10$-0.15 vs $-0.12miss
- Tue, Aug 5$-0.18 vs $-0.16miss
- Tue, May 13$-0.22 vs $-0.27beat
Estimates and results for MASS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
MASShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (7)
- Newsmarketbeat.com·12h ago·Negative
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market 908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
View source ↗ - Newsseekingalpha.com·2d ago·Negative
908 Devices Q2: Another Solid Report 908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
908 Devices: Mission Critical Devices Drive Growth 908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript 908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·4d ago·Negative
908 Devices Q2 Earnings Call Highlights 908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.
View source ↗ - Newszacks.com·4d ago·Negative
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates 908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
View source ↗ - Newsbusinesswire.com·4d ago·Neutral
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026. “We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA los
View source ↗